Therapeutic human immunodeficiency virus (
HIV) vaccines aim to reduce
disease progression by inducing HIV-specific T cells.
Vacc-4x are
peptides derived from conserved domains within HIV-1 p24 Gag. Previously,
Vacc-4x induced T cell responses in 90% of patients which were associated with reduced viral loads. Here we evaluate the effects of
Vacc-4x boosters on T cell immunity and immune regulation seven years after primary immunization. Twenty-five patients on effective antiretroviral
therapy received two
Vacc-4x doses four weeks apart and were followed for 16 weeks.
Vacc-4x T cell responses were measured by proliferation (
CFSE), INF-γ, CD107a,
Granzyme B, Delayed-Type
Hypersensitivity test (DTH) and
cytokines and
chemokines (Luminex). Functional regulation of Vacc-4x-specific T cell proliferation was estimated in vitro using anti-IL-10 and anti-TGF-ß
monoclonal antibodies. Vacc-4x-specific CD8(+) T cell proliferation increased in 80% after either the first (64%) or second (16%) booster. Only 40% remained responders after two boosters with permanently increased Vacc-4x-specific proliferative responses (p=0.005) and improved CD8(+) T cell degranulation, IFN-γ production and DTH. At baseline, responders had higher CD8(+) T cell degranulation (p=0.05) and CD4(+) INF-γ production (p=0.01), whereas non-responders had higher production of proinflammatory TNF-α, IL-1α and IL-1ß (p<0.045) and regulatory
IL-10 (p=0.07). Notably,
IL-10 and TGF-ß mediated downregulation of Vacc-4x-specific CD8(+) T cell proliferation increased only in non-responders (p<0.001). Downregulation during the study correlated to higher PD-1 expression on Vacc-4x-specific CD8(+) T cells (r=0.44, p=0.037), but was inversely correlated to changes in Vacc4x-specific CD8(+) T cell proliferation (r=-0.52, p=0.012). These findings show that
Vacc-4x boosters can improve T cell responses in selected patients, but also induce
vaccine-specific downregulation of T cell responses in others. Broad surveillance of T cell functions during immunization may help to individualize boosting, where assessment of
vaccine-related immune regulation should be further explored as a potential new parameter.